VIRO-IMMUN Labor-Diagnostika GmbH
Superior ELISAs, IFAs and Western Blots.
Influenza A and Influenza B viruses
Influenza is an acute viral disease of the respiratory tract, which occurs in epidemics in winter and early spring. Typical symptoms are fever, malaise, coughs, headache and myalgia (muscle pain) occurring after a short incubation period of 1-3 days. Complications may occur mainly in elderly people in the form of a secondary bacterial pneumonia, which can be life-threatening. Transmission is by droplet infection. The etiological agents of influenza are the Orthomyxoviruses of which 3 types, A, B and C exist. The viral envelope contains two important glycoproteins, Haemagglutatinin (H) and Neuraminidase (N). The Haemagglutinin antigen is most often subject to genetic change (antigen drift, antigen shift). Thus anti-influenza antibodies from previous infections cannot neutralise the new influenza strains. Epidemics of influenza A occur at intervals of 2-5 years, pandemics every 10-15 years. Type B infections remain generally localised, and Type C infections are rare and generally mild. Early vaccination (from September) can prevent or reduce the effects of influenza infection. The antiviral drugs amantadine and its analogue rimantadine are effective treatments during the first 24-48 hours after onset of the influenza infection.
VIR-ELISA ANTI-INFLUENZA A-IgG Art.No. EG 116
VIR-ELISA ANTI-INFLUENZA A-IgA Art.No. EA 116 Intended use
The VIR-ELISA tests ANTI-INFLUENZA A-IgG and ANTI-INFLUENZA A-IgA are enzyme immunoassays for the determination of antibodies to Influenza A viruses in human serum and plasma.
Antigen Characterisation Antigen: Influenza A virus Strain: Texas 1/77 (H3N2), Moscow 10/99 (H3N2), New Caledonia 20/99 (H1N1) Cultivation: chicken eggs Purification: Ultrasonication, centrifugation
VIR-ELISA ANTI-INFLUENZA B-IgG Art.No. EG 117
VIR-ELISA ANTI-INFLUENZA B-IgA Art.No. EA 117
The VIR-ELISA tests ANTI-INFLUENZA B-IgG and ANTI-INFLUENZA B-IgA are enzyme immunoassays for the determination of antibodies to Influenza B viruses in human serum and plasma.
Antigen Characterisation Antigen: Influenza B virus Strain: Hongkong 5/72 Cultivation: embryonary chicken eggs Purification: Ultrasonication, centrifugation
Incubation at room temperature (30’, 30’, 10’)
Individually sealed and vacuum-packed single strips for a long shelf life
Test evaluation Qualitative results Negative result
OD value sample < Cut-off value - 10%
Cut-off value = OD negative control + OD Cut-off control
Equivocal result Positive result
OD value sample > Cut-off value + 10%
Semi-quantification for IgG antibody determination
Two-point quantification. The 2 point - calibration of the VIR-ELISA tests represent a possibility of quantifying anti-body activities in a patient sample by determination of the titre.
For the IgA antibody detection, the results can only be determined qualitatively. Diagnostic relevance
Serum and plasma antibodies persist for over one year. Due to the genetically produced structural changes to the viral coat, specific antibodies produced in previous influenza infections provide no protection against new infections. The determination of IgG and IgA antibodies is useful for the early detection of infection and for monitoring patients. Possible cross reactions should be taken into consideration in the interpretation of results. Cross reactivity between the different Influenza virus types A, B, C cannot be excluded.
VIRO-IMMUN Labor-Diagnostika GmbH , D-61440 Oberursel/Weißkirchen
Section 1: British Pantomimes Part 5: Mid-Sized Pantomimes (with a chorus) (Page 1) (Chorus increases flexibility of numbers.)These shows are a mixture of scripts written for schools and children’s groups, and short pieces written for performance by adults or mixes of adults and children. The quoted run-times are a guideline only; so much depends on an individual production. Aladd